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Atherosclerosis is a chronic inflammatory process of the vessel walls, and CD4+ T-cells are peculiar to both human
and murine atherosclerotic lesions. There is a recent line of research favoring hypothetic allergic mechanisms in the
genesis of atherosclerosis and, consequently, coronary artery disease (CAD), among which Interleukin (IL)-17 appears
to be a key cytokine regulating local tissue inflammation.
The objective was to add a piece of information on the role of IL-17 in the genesis of atherosclerosis. Eighty obese
patients with normal liver enzyme levels but presenting with ultrasonographic evidence of NAFLD formed the
population of this cross-sectional study. Anthropometric measures, data on excess adiposity, metabolic profile,
serum concentrations of IL-17, eotaxin-3, IL-8, and CCL4/MIP1β, C-reactive protein, fibrinogen, ferritin, TNF-α, as well
carotid intima-media thickness (IMT), a marker of atherosclerosis, and the main risk factors for CAD, such as blood
pressure and smoking status, but also less determinant ones such as degree of NAFLD severity, Intramuscular
Triglyceride storage and Resting Metabolic Rate were evaluated.
Serum concentrations of Il-17 were detected as related to those of inflammatory cytokines, IL-6, IFN-γ and TNF-α.
Furthermore, circulating levels of IL-17 were linked to those mirroring allergic process, IL-8, CCL4/MIP1β and eotaxin.
Early atherosclerosis, evidenced as increased IMT, was not associated with circulating IL-17 levels. At multiple regression,
IMT was predicted, other than by age, by the amount of the visceral adiposity, expressed as visceral adipose tissue at
ultrasonography, and by serum eotaxin.
In conclusion, a strong relationship was found between the IL-17-related chemokine eotaxin and IMT. The association
found between the amount of visceral fat and circulating levels of eotaxin on the one hand, and IMT on the other,
could reinforce the hypothesis that IL-17, released by the visceral adipose tissue, induces eotaxin secretion via the
smooth muscle cells present in the atheromatosus vessels.Introduction
Metabolic Syndrome (MS) and obesity, mainly visceral
obesity, are associated with increased mortality due
to Coronary Artery Disease (CAD). Common carotid
Intima-Media Thickness (IMT) is a functional and struc-
tural marker of the atherosclerotic process that leads to
CAD [1]. However, also unclassified Non-Alcoholic Fatty
Liver Disease (NAFLD) or Hepatic Steatosis (non-alco-
holic HS), a further expression of the MS [2], is associated* Correspondence: tarantin@unina.it
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unless otherwise stated.with increased CAD risk [3]. Resting Metabolic Rate
(RMR), by showing an obesity-induced reduced energy
generation for myocardial contractile function, is a novel
biomarker of CAD risk [4]. Intramuscular Triglyceride
(TG) storage (ImTG), easily evaluated by UltraSound due
to an increase in muscle echo intensity [5], was associated
with metabolic risk factors, although most of these asso-
ciations were lost after adjustment for BMI or visceral adi-
pose tissue (VAT), [6].
Starting from the evidence that atherosclerosis is a
chronic inflammatory process of the vessel walls and
that CD4+ T-cells are peculiar to both human and mur-
ine atherosclerotic lesions [7,8], there is a recent line of
research favoring hypothetic allergic mechanisms in
the genesis of atherosclerosis and, consequently, CAD. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to be the regulation of local tissue inflammation via the
coordinated expression of pro-inflammatory cytokines
and chemokines. This cytokine is primarily involved in the
pathogenesis of allergic diseases [11]. The relevance of
IL-17 to human atherosclerosis remains poorly defined
because of the conflicting results available; what is more,
the underlying mechanisms have yet to be unraveled. Re-
sults from animal studies suggest a pro-atherogenic role
for IL-17 [12,13]; in humans, vice versa, an athero-
protective effect of IL-17, through the cross-regulation of
IFN-γ-producing Th1 cells, has been recently proposed
[14]. Accordingly, Simon et al. have found an inverse asso-
ciation between levels of circulating IL-17 and a higher
risk of major cardiovascular events [15].
A recent research has been conducted to assess IL-17-
related cytokine/chemokine interplay using a different
target-organ i.e., cultured bronchial epithelial cells; these
authors demonstrated that treating these cells with
IL-17 plus T(H)2 cytokines induced a strong up-regula-
tion of IL-8, eotaxin-3 and CCL4/MIP1β [16].
IL-17-induced IL-8, as discussed below, is a cytokine
with a pleiotropic effect on cardiovascular homeostasis.
On the other hand, IFN-γ inducible protein, CXCL10/
IP-10, a member of the chemokine family with pro-
inflammatory and anti-angiogenic properties, has been
proposed as a key link between inflammation and angio-
genesis [17], lending credence to its role in inducing
atherosclerosis.
Zeroing in on IMT, we aimed at evaluating the associa-
tions between this marker of atherosclerosis and CAD risk
factors in our study population.
Moreover, to gain further insight into the role of IL-17
in the genesis of atherosclerosis, the serum concen-
trations of IL-17 were correlated, beyond IMT, to estab-
lished CAD risk factors, i.e., blood pressure, smoking
status, High Density Lipoprotein cholesterol (HDL) and
Low Density Lipoprotein cholesterol (LDL), but also less
determinant CAD risk factors such as metabolic fuel
utilization, evaluated as RMR, new parameters positively
associated with subclinical carotid atherosclerosis in
overweight/obese individuals [18], ImTG and NAFLD;
fat excess distribution; metabolic profile; markers of
acute and chronic inflammation; cytokine/chemokine
network generated by IL-17, such as IL-8, CXCL10/
IP-10, CCL4/MIP1β, IFN-γ and eotaxin.
Methods
Study design and population
Our study sample consisted of 125 consecutive obese
adults with NAFLD, without known CAD, referred to
the out-patient metabolic unit from May 2012 to April
2013, all diagnosed at least six months before enroll-
ment. The subjects had been on a balanced low calorie,low fat (25% of calories) diet for three months prior to en-
rolment and were characterized by sedentary life-style.
The research protocols were approved by the Ethics
Committee of the Federico II University Medical School
of Naples (assigned protocol number: 231-05). All partici-
pants provided their written informed consent to partici-
pate in this study. The Department of Clinical Medicine
and Surgery of the Federico II University Medical School
of Naples (Italy) approved the conduction of this study.
For the current analysis, we used residual serum from
a subsample of 80 patients, median age 46 years, re-
cruited during the same period, who had participated in
the parent study on Eotaxin and had agreed to contrib-
ute to this second part. Standard checklist form, which
included information on age, sex, diet, lifestyle, past or
present disease(s), current medications and dosage, self-
reported tobacco products usage (cigarettes brand and
type, cigars, or tobacco for pipes, used in the days before
enrolment, and self-reported tobacco exposure (presence
or absence of smokers at home, at work, or in social
settings).
Detailed descriptions of the inclusion and exclusion cri-
teria of the study design and data collection procedures
have been described elsewhere [10]. Briefly, out of the ini-
tial participants, 12 were excluded due to difficulties in
performing abdominal US for NAFLD screening (intes-
tinal meteorism), nine others because they had taken ste-
roids (six for bronchial asthma, two for rheumatoid
arthritis and one for IBD), and eight who had undergone
therapy with one or more drugs known to alter laboratory
data such as aspirin, statins, fibrates and metformin.
Six patients were excluded for the presence of hepatic
co-morbidities in their history (HBV/HCV infection or
alcohol abuse). Ten patients were excluded for lack of
adherence to the protocol. Every patient gave informed
written consent to participate to this investigation accor-
ding to the principles laid down in the declaration of
Helsinki.
Evaluation of excess adiposity
The three degrees of obesity (light, moderate and severe)
were established on the basis of BMI cut-off points of
30–34.9, 35–39.9 and >40 kg/m2, respectively. MS was
not categorized as a single entity, but analyzing every
criterion. Visceral obesity was identified by measuring
WC at the midpoint between the lower border of the rib
cage and the iliac crest. Hip circumference was mea-
sured around the widest part of the buttocks, with the
tape parallel to the floor, and the Waist to Hip ratio
(WHR) was calculated.
Subcutaneous Adipose Tissue (SAT) and Visceral Adipose
Tissue (VAT) were assessed by transverse scanning using
an eleven linear probe and 3.5 MHz convex probe, re-
spectively. SAT was defined as the thickness between the
Tarantino et al. Journal of Translational Medicine 2014, 12:214 Page 3 of 10
http://www.translational-medicine.com/content/12/1/214skin-fat interface and the linea alba, avoiding compression.
VAT was defined as the distance between the anterior wall
of the aorta and the internal face of the recto-abdominal
muscle perpendicular to the aorta, measured one cm
above the umbilicus. When the aortic walls were not vi-
sualized because obscured by bowel gas, the Doppler scan
was used.
The classification of “bright liver” or HS was based on
the following scale of hyper-echogenity: grade 0 = absent,
grade 1 = light, grade 2 =moderate, grade 3 = severe,
pointing out the difference between liver densities and
the right kidney [19]. Mean brightness levels of both
liver and right kidney cortex were obtained on the same
longitudinal sonographic plane.
Muscle ultrasound, performed at the level of the biceps
muscle of the left superior arm, is a convenient technique
to visualize pathological muscle tissue, as it is non-
invasive and provides results in real-time. Both infiltration
of fat and fibrous tissue increase muscle echo intensity,
i.e., the muscles become whiter at the ultrasound image
[20]. To describe muscle echo intensity, Heckmatt and co-
workers developed a visual grading scale where grade I
represented normal muscle and grade IV a severely in-
creased muscle echo intensity with total loss of bone echo
(we chose biceps versus humerus), [21]. The levels of
brightness of the liver and the biceps were calculated three
times directly from the frozen images.
Atherosclerosis and caronary artery disease risk factors
The common carotid, the carotid bulb and the near and
far wall segments of the internal carotid were scanned bi-
laterally. Subjects were examined in the supine position
with the head turned 45° contra-lateral to the side under-
going scanning. Images were obtained in longitudinal sec-
tion, with a single lateral angle of isonation, optimizing
the image for the far wall. IMT was defined as the distance
between the lumen-intima and the media-adventitia ultra-
sound interfaces. Measurements were performed off-line
and consisted of six manual measurements at equal dis-
tances along 1 cm on the far wall of the common carotid.
Left and right IMT were averaged [22].
Systolic/Diastolic Arterial Pressure (SBP, DBP) was the
average of three consecutive readings taken after allo-
wing the subjects to rest for five minutes in the sitting
position.
RMR was measured by indirect calorimetry using a can-
opy system (V max 29 N, Sensor Medics, Anaheim, USA)
in a quiet environment and with patients in the supine
position for 30 min before measurement. After a 15–
20 min adaptation to the instrument, oxygen consumption
and carbon dioxide production were determined for
45 min. Energy expenditure was derived from CO2 pro-
duction and O2 consumption with the appropriate Weir
formula neglecting protein oxidation [23]. BMR, expressedas kcal/24 h, was adjusted for changes in fat-free mass
(FFM)], which was evaluated by single-frequency bio-
impedance analysis obtaining an RMR/FFM ratio, ex-
pressed as kcal/24 h*kg of body [24].
Age and smoking status were also considered impor-
tant risk factors.
Inflammatory markers
The methods used to assess circulating IL-6 and TNF-α
are described below. C reactive protein (CRP) values
were determined by a high-sensitivity ELISA test, with
reference values between 0.3 and 8.6 mg/L in healthy
men and between 0.2 and 9.1 mg/L in healthy women
(BioCheck, Inc, CA, USA). Ferritin and fibrinogen were
performed by in-house standard procedures.
Metabolic profile
Serum Triglycerides (TG), HDL, LDL, basal insulin,
were determined by standard methods. IR status was de-
termined by the HOmeostatic Metabolic Assessment
(HOMA), which was assessed by the following formula:
fasting insulin (μU/mL) x fasting glucose (mg/dL)/405.
Moreover, as the repeated HOMA measurements pre-
sented high within-person variability in obese patients,
HOMA values were averaged on the basis of several de-
terminations to avoid misclassification.
Bead-based assay
Human IL-17 singleplex was performed according to Bio-
Rad systems protocol (Bio-Rad Lab., Inc., Hercules, CA,
USA) as elsewhere reported [25,26]. Sera samples were di-
luted four times with a suitable buffer. Initially, the 96-well
filter bottom plate was pre-wet. Fifty microliters of diluted
microparticle solution and 50 μl of sample were added to
each well in duplicate. Thereafter, the plate was incubated
for 1 h and washed three times with wash buffer. After-
wards, 25 μl of diluted biotin antibody were added to each
well and incubated for 1 h. The plate was then washed as
described above, and 50 μl of diluted Streptavidin-PE were
added to each well and incubated for 10 min. All incuba-
tions were performed at room temperature on an orbital
shaker set at 15 g. Finally, the plate was washed again with
100 μl of wash buffer. The median relative fluorescence
units were measured using the Luminex 200 analyzer
(Luminex, Austin, TX, USA). IL-17 concentrations were
calculated using a standard curve. Control range used for
IL-17 was 52,89 ± 41,79 pg/mL.
The coefficient of variation, calculated by SD/mean × 100
for the intra-assay and inter-assay was <10% and <12%,
respectively.
To establish whether IL-17 levels correlated with other
cytokines, the following molecules present in Human
Cytokine 27-Plex Panel (Bio-Rad Lab., Inc., Hercules,
CA, USA), i.e., IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7,
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(CCL11), basic FGF, G-CSF, GMCSF, IFN-γ, IP-10
(CXCL10), MCP-1 (CCL2), MIP-1a (CCL3), MIP-1β
(CCL4), PDGF-bb, RANTES (CCL5), TNF- α and VEGF,
were evaluated by the same procedure reported above, the
control range of which was: for IL-17: 52.89+/−41.79 pg/mL,
eotaxin 19.4+/−7.2 pg/mL, IL-8: 18.04+/−2.09 pg/mL,
IP-10 (CXCL10): 242.09+/−52.67 pg/mL, CCL4/ MIP-1β:
22.51+/−9.65 pg/mL, IFN-γ: 19.79+/−3.26 pg/mL, for
IL-6: 4.01+/−2.58 pg/mL, for TNF-α : 5.76+/−3.44 pg/mL.Remainders
Blood samples were drawn into 9-mL serum tubes, with
participants in the fasting state. Samples were centrifuged
for 10 min at RCF of 850–1000, collected, aliquoted, and
frozen at −20°C until analysis. Alanine aminoTransferase
(ALT), Pseudo Cholinesterase (PCH), Alkaline Phospha-
tase (AP), Gamma Glutamyl Transpeptidase (gamma-GT)
were obtained following standard procedures.Table 1 Characteristics of obese patients with NAFLD (n 80)
Parameter Mean+/−SD or median plus (25–75 IQR)
Age (years) 46 (34–53)
Gender M/F 36/44
Obesity Degree I/II/III (n) 18/26/46
BMI 42.3 (38.1-46.8)
WC Females (cm) 118.9+/−12.5
WC Males (cm) 129.3+/−14
WHR Females 0.95 (0.93-0.97
WHR Males 0.98 (0.96-1)
HS Grade 1/2/3 at US (n) 22/48/10
SAT (cm) 2.6 (2.1-3.1)
VAT (cm) 7.5 (6–9.4)
ImTG Score I/II/III/IV at US(n) 11/23/30/16
ALT (U/L) 28 (21.5-29)
CHE (U/L) 9671.4+/−1882.2
AP (U/L) 73 (61–91)
γ-GT(U/L) 25 (16.5-42.5)
HS grade at US 1/2/3 (n) 22/50/8
IMT (mm) 0.09 (0.07-011)
SBP mm Hg 130 (120–140)
DBP mm Hg 80 (80–90)
Smoking status (yes/no) 42/38
Waist Circumference WC, Body Mass Index BMI, Waist to Hip ratio WHR, Subcutaneous A
HDL, Low Density Lipoprotein LDL, TriGlycerides TG, C Reactive Protein CRP, Spleen Lo
Interleukin-8 IL-8, C-X-C motif chemokine 10 (CXCL10) also known as Interferon Gamm
MIP1β, Interferon-Gamma IFN-γ UltraSound US, ALanine aminoTransferase ALT, CHolin
fasting glucose, High Density Lipoprotein cholesterol HDL, HOmeostatic Metabolic Ass
Intima-Media Thickness IMT Resting Metabolic Rate RMR, Intramuscular Triglyceride (TGStatistics
Age, BMI, WHR, SAT, VAT, ALT, AP, γ-GT, HOMA, SBP,
DBP, common carotid IMT, TG, CRP, fibrinogen, ferritin,
eotaxin, fasting glucose, IFN-γ, IP-10 (CXCL10), MIP-1β
(CCL4), IL-17, IL-8, IL-6, TNF- α were not normally dis-
tributed when analyzed by the Shapiro-Wilk (S-W) test,
p < 0.05, and were expressed as median plus 25–75 inter-
quartile range (IQR). Data for WC, CHE, HDL cho-
lesterol, derived from a normally distributed population
(S-W, p > 0.05), were articulated as mean plus SD. Smo-
king status, categorized as present/absent, was analyzed in
relation to its role influencing IMT by means of the two-
tailed Mann–Whitney test for independent samples,
expressed as median plus 95% CI for the median. At uni-
variate analysis, to assess the independent effect of a quan-
titative variable on the prediction of another one, the
linear regression analysis (least squares) was used, evalua-
ting the coefficient with its standard error, 95% confidence
intervals (CI) and t (t-value). A t-value above 1.96 with a
significance below 0.05 indicates that the independentParameter Mean+/−SD or median plus (25–75 IQR)
HDL Females mg/dL 49.3+/−15
HDL Males mg/dL 42.7+/−9
TG mg/dL 123.5 (83.5-188)
CRP mg/mL 0.56 (0.27-1.3)
Fibrinogen g/L 295.5 (256–357.5)
Ferritin Females ng/mL 41.5 (20–69)
Ferritin Males ng/mL 167.5 (85–234)
SLD cm 11.3+/−1.5
RMR 2352.2+/−432.7
Eotaxin pg/mL 24.6 (6.17-77.5)
TNF- α pg/mL 41.8 (8.1-112.7)
IL-6 pg/mL 5.7 (2.3-17.5)
IL-8 pg/mL 23.1 (3.3-68.1)
IFN-γ pg/mL 158 (56–390)
IP-10 (CXCL10) pg/mL 405 (255–659)
MIP-1β (CCL4) pg/mL 37.2 (24.3-51.9)
Fasting insulin μU/mL 10.9 (7.5-15.8)
Fasting glucose mg/dL 96.5 (87–114)
HOMA 2.78 (1.85-4.18)
LDL 66.8 (33.3-140)
dipose Tissue SAT, Visceral Adipose Tissue VAT, High Density Lipoprotein-cholesterol
ngitudinal Diameter SLD, Tumor Necrosis Factor alpha TNF-α, Interleukin-6 IL-6,
a-induced protein 10 (IP-10) CXCL10/IP-10, Chemokine (C-C motif) ligand 4 CCL4/
Esterase CHE, Alkaline Phosphatase AP, Gamma-Glutamyl Transglutaminase γ-GT,
essment HOMA, Systolic Blood Pressure SPP, Diastolic Blood Pressure DBP,
) storage Score ImTG.
Tarantino et al. Journal of Translational Medicine 2014, 12:214 Page 5 of 10
http://www.translational-medicine.com/content/12/1/214variable is a significant predictor of the dependent variable
within and beyond the sample. To establish the best
combination of independent (predictor) variables able to
predict the dependent (predicted) variable, multiple re-
gression (Stepwise Selection) was adopted firstly entering
all independent variables if p = <0.05 into the model, and
then removing if p= >0.1 the non-significant variables
sequentially, with a maximum number of 10 steps; this
produced two different analyses, i.e., IL-17 or IMT used as
dependent variable, in the first and second model, respect-
































Linear Regression using Eotaxin as depedent variable. Waist Circumference WC, Body M
Visceral Adipose Tissue VAT, C Reactive Protein CRP, Spleen Longitudinal Diameter SLD
Phosphatase AP, Gamma-Glutamyl Transglutaminase γ-GT, High Density Lipoprotein H
Systolic Blood Pressure SPP, Diastolic Blood Pressure DBP, Intima-Media Thickness IMT
IP-10, Chemokine (C-C motif) ligand 4 CCL4/MIP1β, Interferon-Gamma IFN-γ, Intramusc
10 CXCL10/IP-10, Chemokine (C-C motif) ligand 4 CCL4/MIP1β, Interferon-Gamma IFN-
Interleukin-17 IL-17.the predictors are correlated with each other to some de-
gree, the variance inflation factor and tolerance were set
at >10 and <0.1, respectively. Similarly, to get the sense of
which variables contribute more or less to the regression
equation, the magnitude of standardized coefficient beta
(β) was calculated. Finally the zero order correlation coef-
ficients, indicating the simple correlation coefficients,
were evaluated.
To evaluate intra/inter-observer variability of the mea-
surements, the mean difference in the measurements of
the observers was first calculated. Next, the concordance95% CI t P
−2.40 to 2.26 −0.062 0.95
−1.21 to 6.89 1.39 0.16
−286.7 to 964.01 0.28 0.28
−37.10 to 48.39 0.26 0.79
−6.89 to 18.83 0.92 0.35
−0.087 to 0.77 1.58 0.11
−12.97 to 17.33 0.28 0.77
−27.61 to 14.52 −0.61 0.53
−0.34 to 0.13 −0.84 0.4
0.94 to 1.21 15.9 <0.0001
3.89 to 6.42 8.1 <0.0001
0.39 to 0.49 18.0 <0.0001
−45.96 to 65.39 0.34 0.72
−2.75 to 1.31 −0.70 0.48
−0.03 to 0.004 −1.47 0.14
−1.24 to 1.25 0.009 0.99
−1.56 to 1.66 0.061 0.95
1.55 to 1.90 20.01 <0.0001
−0.069 to 0.076 0.087 0.93
2.53 to 4.33 7.6 <0.0001
0.45 to 1.11 4.73 <0.0001
−3.42 to 2.13 −0.46 0.6460
−0.21 to 0.45 0.7 0.48
−8.26 to 8.54 0.032 0.97
−0.23 to 0.48 0.69 0.48
−691.95 to 1241.96 0.56 0.57
−0.68 to 1.03 0.41 0.68
−4.32 to 3.60 −0.17 0.85
−0.070 to 0.081 0.15 0.87
−19.94 to 49.5 0.84 0.39
ass Index BMI, Waist to Hip ratio WHR, Subcutaneous Adipose Tissue SAT,
, UltraSound US, ALanine aminoTransferase ALT, CHolinEsterase CHE, Alkaline
DL, Low Density Lipoprotein LDL, HOmeostatic Metabolic Assessment HOMA,
, Resting Metabolic Rate RMR, C Interferon gamma-induced protein 10 CXCL10/
ular Triglyceride (TG) storage Score ImTG, C Interferon Gamma-induced protein
γ, Tumor Necrosis Factor alpha TNF-α, Interleukin-6 IL-6, Interleukin-8 IL-8,
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accuracy, was adopted to evaluate the degree of pair
observations at US, with values >0.8 considered as indi-
cators of good reliability. MedCalc, version 13.2 (MedCalc
Software, Broekstraat 52, 9030 Mariakerke, Belgium)
and SyStat 13 (Cranes Software International, Bangalore,
India) were the packages used for the statistics.
Results
Demographic characteristics, anthropometric parameters/
US features evaluating excess adiposity, metabolic profile,
inflammatory markers, IMT and coronary artery disease
risk factors are reported in Table 1. This clearly shows that
patients were affected mainly by II and III degree obesity;
some patients (n 11, 13%) did not present ImTG and most
of them were characterized by mild/moderate HS (n 60,
75%). Noteworthy are the normal or slightly elevated
values of liver enzymes in these obese patients, who ne-
vertheless presented liver fat storage excess. Finally, the
metabolic profile, the borderline median IMT and blood
pressure values of our series were not particularly altered,
showing that they were selected to study a homogeneous
population without unbalanced CAD risks. Thirty-two of
80 patients enrolled reported to be active smokers, and
ten passive smokers. Twenty-two subjects had never






















Figure 1 Graphics of the main predictions between IL-17 and other im
confidence interval as dot line and 95% prediction interval as continuous line
Interleukin-17 IL-17, Interleukin-8 IL-8.the two groups , i.e., 0.09 (0.08-0.11) and 0.08 (0.08-0.10)
median plus (95% CI of median), respectively, P = 0.60.
Among the cytokine/chemokine network, our data
highlighted a significant increase in circulating TNF-α,
Eotaxin, IL-8 and IFN γ levels, whereas serum IL-6 and
CCL4/MIP1β were slightly elevated.
The intra/inter-observational variability of the US esti-
mations was not significant, the mean difference being
equal to 1.7, 2.2, 2.5, 2.3 and 1.9%, and 2.1, 3.3, 3.9, 4.6,
and 3. 1% for the HS, VAT, SAT, SLD and common
carotid IMT, respectively, with a ρc of 0.92.
Predictions
The main findings were firstly that, at univariate analysis,
serum concentrations of Il-17 were not associated with
IMT. Secondly, circulating concentrations of Il-17 were
related to the levels of specific inflammatory/immune re-
gulators, such as TNF α, IL-6, IL-8, IFN γ, CCL4/MIP1β,
Eotaxin, but not of other inflammatory parameters such
as CRP, fibrinogen and ferritin (Table 2). Noteworthy were
the strict relationships between serum IL-17 and the pa-
rameters strongly up-regulated in allergic/hyperergic reac-
tions, such as eotaxin, IL-8, and CCL4/MIP1β (Table 2,
Figure 1). Similarly, IL-8 and eotaxin were the best com-
bination of predictors of their serum levels at multivariate





















mune parameters. At the centre the regression line is evidenced; 95%
, Chemokine (C-C motif) ligand 4 CCL4/MIP1β, Interferon-Gamma IFN-γ,
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http://www.translational-medicine.com/content/12/1/214predicted by the fat deposition in the abdominal, liver and
muscle districts, specifically, the thickness of visceral adi-
posity expressed as VAT, the grade of HS at US, the de-
position of TG in muscle, i.e., ImTG, by an IL-17-induced
chemokine, i.e., circulating eotaxin, and a marker of
chronic inflammation, i.e., serum ferritin, but not by the
smoking status (Table 3). Insulin resistance, evaluated as
HOMA, and anthropometric features such as BMI, WC
and WHR were not associated with serum IL-17 levels,
































Linear Regression using IMT as dependent variable. Waist Circumference WC, Body
Visceral Adipose Tissue VAT, C Reactive Protein CRP, Spleen Longitudinal Diameter SLD
Phosphatase AP, Gamma-Glutamyl Transglutaminase γ-GT, High Density Lipoprotein H
Systolic Blood Pressure SPP, Diastolic Blood Pressure DBP, Intima-Media Thickness IMT
ligand 4 CCL4/MIP1β, Interferon-Gamma IFN-γ, Tumor Necrosis Factor alpha TNF-α, Int
categorized as present/absent.HS, SAT, VAT and ImTG, related to the same cytokine
(Table 3).
When the interplay of cytokine/chemokine was evalu-
ated at the multivariate analysis, the best combination of
predictors of circulating IL-17 levels were serum IL-8 and
serum eotaxin, (Table 4, top). Again, when evaluating the
main risk factors for early atherosclerosis at the multi-
variate analysis, the amount of visceral fat, expressed as
VAT, and circulating eotaxin levels were the best com-
binations in predicting IMT (Table 4, bottom). Afterariable studied
95% CI t P
−0.0003 to 0.0007 0.70 0.48
−0.0008 to 0.001 0.14 0.88
−0.05 to 0.23 1.3 0.19
−0.017 to 0.0018 −1.6 0.11
0.0016 to 0.007 3.1 0.0023
−0.0001 to 0.00008 −0.29 0.76
−0.004 to 0.0028 −0.39 0.69
−0.006 to 0.003 −0.5 0.61
0.000005 to 0.0001 2.18 0.031
0.004 to 0.029 2.7 0.0084
−0.0005 to 0.0004 −0.11 0.90
−0.000004 to 0.000003 −0.22 0.82
−0.0005 to 0.00005 −1.57 0.11
−0.0001 to 0.0006 1.39 0.16
−3.42 to 2.13 −0.46 0.64
−0.00005 to 0.0001 0.66 0.51
−8.26 to 8.54 0.032 0.97
−0.23 to 0.48 0.69 0.48
−2.20 to 4.4 0.67 0.50
−0.00008 to 0.0009 1.65 0.10
−0.0005 to 0.0012 0.81 0.41
−3048.9 to 2694.5 −0.12 0.90
0.0012 to 0.016 2.30 0.024
−3121.47 to 2863.73 −0.085 0.93
−0.0002 to 0.0003 0.33 0.73
144.34 to 1265.95 2.50 0.014
−1310.40 to 2560.32 0.64 0.52
−472.41 to 551.44 0.15 0.87
−99.87 to 154.03 0.42 0.67
−267.77 to 1284.03 1.30 0.19
Mass Index BMI, Waist to Hip ratio WHR, Subcutaneous Adipose Tissue SAT,
, UltraSound US, ALanine aminoTransferase ALT, CHolinEsterase CHE, Alkaline
DL, Low Density Lipoprotein LDL, HOmeostatic Metabolic Assessment HOMA,
, C Interferon Gamma-induced protein 10 CXCL10/IP-10, Chemokine (C-C motif)
erleukin-6 IL-6, Interleukin-8 IL-8, Interleukin-17 IL-17. The smoking status was
Table 4 Best combination of cytokines pattern able to
predict IL-17 and of factors predicting the intima-media
thickness
Dependent Y IL-17
Independent variables Coefficient Std. error β t P
IL-8 1.61 0.085 0.90 18.9 <0.0001
Eotaxin 0.28 0.074 0.39 3.79 0.0003
Variables not included in the model IL-6, TNF-α, CCL4/MIP1β
Zero order correlation coefficients:
IL-8: r 0.91, IL-6: r 0.67, TNF-α : r 0.87, CCL4/MIP1β: r 0.65, Eotaxin: r 0.47
Dependent Y IMT
Independent variables Coefficient Std. Error β t P
Eotaxin 0.00011 0.000039 0.30 2.8 0.0059
VAT 0.0046 0.0013 0.36 3.4 0.0010
Variables not included in the model: smoking status ,ferritin, HS grade at
US, ImTG score at US, age, LDL,
Zero order correlation coefficients:
Eotaxin: r 0.27, VAT: r 0.33, ferritin: r 0.24, HS grade at US: r 0.29, ImTG
score at US: r 0.25
The latter model adjusted for Age
Dependent Y IMT
Independent variables Coefficient Std. Error β t P
Eotaxin 0.0027 0.000032 0.32 2.8 0.0059
VAT 0.0014 0.0011 0.26 3.4 0.0010
AGE 0.0014 0.00023 0.58 6.20 <0.0001
Zero order correlation coefficients: Eotaxin: r= 0.27, r= VAT: r= 0.33, Age r= 0.61.
Multiple Regression Equations, Stepwise Method, using IMT or IL-17 as
dependent variables. In blue is evidenced the regression line; in dark red the
95% prediction and in light red the 95% prediction. Chemokine (C-C motif)
ligand 4 CCL4/MIP1β, Interferon-Gamma IFN-γ, Interleukin-17 IL-17, Interleukin-8
IL-8 C, Tumor Necrosis Factor alpha TNF-α, Interleukin-6 IL-6, Interleukin-17 IL-17.
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remained unchanged. After adjusting the IMT prediction
for other risk factors of atherosclerosis, i.e., adding LDL
values, HOMA and smoking status, the amount of vis-
ceral fat, evaluated by US, and the circulating eotaxin
levels in this population, remained predictors. Ob-
viously, age played a predominant role in the adjusted
model, Table 4 (third part).
Surprisingly, serum Il-17 was an independent pre-
dictor of IFN-γ levels.
Among the anthropometric measures, i.e., BMI, WHR
and WC, only WC was associated only to VAT at US
coefficient 0.097; Std. Error0.021; 95% CI 0.46 to 4.57;
P = <0.0001.
Discussion
Evidencing the key-points of this research, firstly, serum
Il-17 concentrations were associated with those of IL-6,
IFN-γ and TNF-α on the one hand (inflammatory cyto-
kines), and to IL-8, CCL4/MIP1β, and eotaxin on the
other hand (allergic/hyperergic cytokines, all induced byIL-17). Secondly, early atherosclerosis, evidenced as
increased thickness of the arterial intima-media, was
strongly predicted, other than by age, by the amount of
visceral adiposity, expressed as VAT, and by circulating
eotaxin.
The former finding confirms the body of pertinent
knowledge that IL-17, induced by IL–23, acts as a potent
mediator in delayed-type reactions by increasing cyto-
kines/chemokine production from other cell types i.e.,
fibroblasts and macrophages beyond endothelial and epi-
thelial cells, the classic model of which being bronchial
asthma [27].
The latter finding confirms that an interplay between
alterations of adipose tissue distribution and its function
with broad effects on cytokine/chemokines in the induc-
tion/maintenance of atherosclerosis could be evidenced,
although a direct effect of IL-17 on vascular walls was
lacking.
Discussing possible mechanisms and explanations for
the link between the amount of visceral fat on the one
hand, circulating levels of IL-17-related chemokine –
i.e., eotaxin as well – and IMT on the other hand, we
hypothesize that IL-17, produced by the macrophages of
visceral adipose tissue, functioning as immune organ,
[28] induces eotaxin secretion by the smooth muscle
cells present in the atheromatosus vessels, only via acti-
vated cells, after a stimulus by TNF-α [29]. In agreement
with our findings on circulating IL-8 levels, it has been
recently evidenced that serum concentrations of this
cytokine mirror the impaired coronary circulation [30].
This interpretation is supported by the composition of
adipose-resident immune cell populations, i.e., macro-
phages, in obese individuals and animals. In obese indi-
viduals, fat cells may act like inflammatory white blood
cells by using communication machinery once consi-
dered to be peculiar to immune cells. Among others,
obesity, is associated with increased IL-17A production
in humans [31]. Mirroring this, Th17 cell expansion is
observed in obese mice [32]. In response to calorie
excess, mice lacking IL-17 exhibit protection from glu-
cose impairment, despite an increased weight gain [33].
Nevertheless, the results of our study are at variance
with previously published works proposing an athero-
protective role for IL-17 [14,15]. Vice versa, our data are
in favor of an indirect pro-atherosclerotic role of IL-17,
in agreement with data from animal studies [12,13]. To
reinforce this hypothesis, there is a recent finding that
IL-17 enhances the production of the von Willebrand
factor by human endothelial cells, and induces endothe-
lial cell apoptosis by activating caspase-3 and caspase-9
and up-regulating the ratio of Bax/Bcl-2, suggesting a
role for IL-17 in vascular endothelial damage [34]. The
role of NAFLD in predicting CAD risk, well established
in the literature [35], is further supported by our data.
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tween ImTG and IMT, lending credence to the view that
ectopic fat storage, also in the muscle, is a sign of insulin
resistance [36], resulting central to major cardiovascular
events. The link found between ferritin and IMT, is not
dampened by the results of a study evaluating the relation-
ship between body iron status and carotid atherosclerosis
in middle-aged eastern Finnish men [37], because our esti-
mate was obtained pooling data of both men and women.
A significant role for CXCL10/IP-10 in increasing
arterial thickness was not evidenced in our series, dif-
ferently from previous results [17].
Commenting on IFN-γ, our data do not seem to confirm
its protective role in early atherosclerosis – expressed as
increased carotid intima-media thickness, due to the fact
that its circulating levels in our population were not in-
versely associated with IMT; this finding is in contrast
with data from an aforementioned study [14]. To reinforce
our line of research, a strong positive relationship between
serum IL-17 and serum IFN-γ was evidenced.
Coming back to another IL-17-related cytokine, IL-8
induces homing of neutrophils that contribute to myo-
cardial injury [38]. In clinical studies, circulating IL-8
levels were higher in patients with acute myocardial in-
farction or unstable angina as compared to controls [39],
representing a good predictor of CAD [40]. Our data on
patients with early atherosclerosis are in support of the
aforementioned results. It should be stressed that the be-
havior of IL-8 changes in the advanced phases of CAD,
becoming this cytokine cardio-protective, at least in ani-
mal models [41].
As to the limitations of the present study, firstly, the type
of study did not allow us to draw conclusions on the direc-
tion of the association. In fact, the cross-sectional nature of
this design does not fulfil the temporal criteria needed to
study the natural history of atherosclerosis. Another pos-
sible pitfall was the lack of artery wall biopsy and sub-
sequent culture of myofibroblasts to detect Il-17 tissue
expression. Neither was adiposity evaluated by the more
precise MRI, nor was arterial stiffness – judged by experts
as a marker of asymptomatic atherosclerosis [42] – de-
tected by means of pulse wave velocity. We should mention
that crucial future research will be directed towards the
study of the TH17/TREG cytokines [43] and human angio-
genesis/growth factors, in the context of visceral adiposity,
which is reckoned as decisive in predicting CAD [44].
Conclusion
Our research lends credence to a possible indirect role of
IL-17 in determining or favoring early, sub-clinical athero-
sclerosis in obese patients, in the sense that its circulating
levels, strongly linked to those of eotaxin could be the
expression of allergic–hyperergic mechanisms triggering
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